FEBS Open Bio (Sep 2024)

Gene expression and characterization of clonally derived murine embryonic brown and brite adipocytes

  • Cristina Velez‐delValle,
  • Claudia Patricia Hernandez‐Mosqueira,
  • Lidia Itzel Castro‐Rodriguez,
  • Alfredo Vazquez‐Sandoval,
  • Meytha Marsch‐Moreno,
  • Walid Kuri‐Harcuch

DOI
https://doi.org/10.1002/2211-5463.13861
Journal volume & issue
Vol. 14, no. 9
pp. 1503 – 1525

Abstract

Read online

White adipocytes store energy, while brown and brite adipocytes release heat via nonshivering thermogenesis. In this study, we characterized two murine embryonic clonal preadipocyte lines, EB5 and EB7, each displaying unique gene marker expression profiles. EB5 cells differentiate into brown adipocytes, whereas EB7 cells into brite (also known as beige) adipocytes. To draw a comprehensive comparison, we contrasted the gene expression patterns, adipogenic capacity, as well as carbohydrate and lipid metabolism of these cells to that of F442A, a well‐known white preadipocyte and adipocyte model. We found that commitment to differentiation in both EB5 and EB7 cells can be induced by 3‐Isobutyl‐1‐methylxanthine/dexamethasone (Mix/Dex) and staurosporine/dexamethasone (St/Dex) treatments. Additionally, the administration of rosiglitazone significantly enhances the brown and brite adipocyte phenotypes. Our data also reveal the involvement of a series of genes in the transcriptional cascade guiding adipogenesis, pinpointing GSK3β as a critical regulator for both EB5 and EB7 adipogenesis. In a developmental context, we observe that, akin to brown fat progenitors, brite fat progenitors make their appearance in murine development by 11–12 days of gestation or potentially earlier. This result contributes to our understanding of adipocyte lineage specification during embryonic development. In conclusion, EB5 and EB7 cell lines are valuable for research into adipocyte biology, providing insights into the differentiation and development of brown and beige adipocytes. Furthermore, they could be useful for the characterization of drugs targeting energy balance for the treatment of obesity and metabolic diseases.

Keywords